Memorial Sloan-Kettering Cancer Center (MSKCC) Memorial Sloan Kettering Cancer Center (MSKCC) is a free-standing institution dedicated to the control of cancer through in-patient and out-patient care, clinical and research training programs, and a broad spectrum of research activities. MSKCC's research programs are grouped into three categories: Basic Research (Regulation of Cell Behavior, Developmental Biology, Genomic Integrity, and Molecular Structure);Bridge Disciplines (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Sciences), and Patient-Oriented Research (Clinical Research and Prevention, Control, and Population Research). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based investigators and to encourage the application of discoveries in the basic sciences in a way that advances the prevention, detection, diagnosis, and treatment of many forms of cancer. Scientific work in the ten research programs depends on services provided by 34 core facilities, 19 of which will receive funding from the Cancer Center Support Grant (CCSG). During the next five years, MSKCC will continue to enlarge its clinical and research facilities and its research and training programs;therefore, an expanded budget is requested to establish the laboratories of new investigators in several fields of inquiry and to support the core facilities which have grown to support the needs of the research enterprise.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA008748-44S5
Application #
7933199
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
2009-09-30
Project End
2012-09-29
Budget Start
2009-09-30
Budget End
2012-09-29
Support Year
44
Fiscal Year
2009
Total Cost
$3,625,922
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Davis, Mellar P; Pasternak, Gavril; Behm, Bertrand (2018) Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option. Drugs 78:1211-1228
Suzawa, Ken; Offin, Michael; Lu, Daniel et al. (2018) Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer. Clin Cancer Res :
Horvat, Joao V; Durando, Manuela; Milans, Soledad et al. (2018) Apparent diffusion coefficient mapping using diffusion-weighted MRI: impact of background parenchymal enhancement, amount of fibroglandular tissue and menopausal status on breast cancer diagnosis. Eur Radiol 28:2516-2524
Al Efishat, Mohammad A; Attiyeh, Marc A; Eaton, Anne A et al. (2018) Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Surg 268:340-347
Dickson, Brendan C; Sung, Yun-Shao; Rosenblum, Marc K et al. (2018) NUTM1 Gene Fusions Characterize a Subset of Undifferentiated Soft Tissue and Visceral Tumors. Am J Surg Pathol 42:636-645
Gao, Yiming; Quinn, Brian; Pandit-Taskar, Neeta et al. (2018) Patient-specific organ and effective dose estimates in pediatric oncology computed tomography. Phys Med 45:146-155
Yang, Lin; Alyasova, Anna; Ye, Dingwei et al. (2018) RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis. BMC Cancer 18:195
Majumdar, Susruta; Devi, Lakshmi A (2018) Strategy for making safer opioids bolstered. Nature 553:286-288
Freites-Martinez, Azael; Shapiro, Jerry; van den Hurk, Corina et al. (2018) CME Part 2: Hair disorders in cancer survivors Persistent chemotherapy-induced alopecia, persistent radiotherapy-induced alopecia, and hair growth disorders related to endocrine therapy or cancer surgery. J Am Acad Dermatol :
Barbetta, Arianna; Nobel, Tamar B; Sihag, Smita et al. (2018) Neutrophil to Lymphocyte Ratio as Predictor of Treatment Response in Esophageal Squamous Cell Cancer. Ann Thorac Surg 106:864-871

Showing the most recent 10 out of 8799 publications